News & Updates
最新消息
Our protocol in Journal of Visualized Experiments describes a time-lapse live-cell imaging method for visualizing and quantifying anti-CD24 antibody-dependent macrophage phagocytosis of GFP-labeled triple-negative breast cancer cells.
本實驗室發表於 Journal of Visualized Experiments 的方法論文，建立以縮時活細胞影像觀察並定量抗 CD24 抗體依賴性巨噬細胞吞噬 GFP 標記三陰性乳癌細胞的標準化流程。
Our spin-off team “MacroForce” (巨噬原力), led by Dr. Shih-Hsuan Chan, won the highest honor — the Entrepreneurship Excellence Award (sponsored by TSMC) — along with the Outstanding Entrepreneurship Award at the final of the 2026 first-batch FITI (From IP to IPO) program held by NSTC / NARLabs on June 16, 2026, receiving an NT$1 million startup fund. The team's therapeutic humanized anti-CD24 monoclonal antibody Phagokil (噬癌平) for triple-negative breast cancer boosts macrophage phagocytosis up to 10-fold and achieves over 95% tumor inhibition in preclinical models.
本實驗室衍生團隊「巨噬原力」由詹世萱副教授領軍，於 2026 年 6 月 16 日國科會／國研院「創新創業激勵計畫（FITI）」115 年第一梯次決選暨頒獎典禮中，榮獲最高榮譽「創業卓越獎」（台積電新興業務開發處贊助）及「創業傑出獎」，並獲頒 100 萬元創業金。團隊研發治療三陰性乳癌的治療性人源化 CD24 單株抗體「噬癌平（Phagokil）」，可精準活化巨噬細胞吞噬功能達 10 倍，臨床前腫瘤抑制率達 95% 以上。
Dr. Chan participated in academic lectures, teacher community activities, and received awards recognizing research excellence in January 2026.
詹博士於 2026 年 1 月參與學術演講、教師社群活動，並榮獲多項表彰研究卓越的獎項。
Our technology “Precision Immunotherapy of Triple-Negative Breast Cancer with a Therapeutic Humanized Anti-CD24 Monoclonal Antibody” (Shih-Hsuan Chan, Lu-Hai Wang) was selected as one of 83 winning technologies of the 2025 Future Tech Award announced by the National Science and Technology Council on September 4, 2025, and was exhibited at the Future Tech Pavilion of Taiwan Innotech Expo.
本實驗室技術「治療性人源化 CD24 單株抗體應用於三陰性乳癌的精準免疫標靶治療」（詹世萱、王陸海）獲選 2025 未來科技獎。國科會於 2025 年 9 月 4 日公布全國 83 件獲獎技術，並於台灣創新技術博覽會「未來科技館」展出。
Our latest study in Journal of Biomedical Science reveals how CD24a knockout promotes M1 macrophage infiltration and cytotoxic CD8+ T cell recruitment in tumor environments.
本實驗室最新發表於 Journal of Biomedical Science 的研究揭示 CD24a 基因剔除如何促進腫瘤微環境中 M1 巨噬細胞浸潤及細胞毒性 CD8+ T 細胞的招募。
Collaborative study reveals how ST6GAL1-mediated sialylation of PECAM-1 promotes lung tropism of metastatic breast cancer, published in Cancer Research.
與國衛院李華容實驗室合作研究揭示 ST6GAL1 介導的 PECAM-1 唾液酸化如何促進轉移性乳癌的肺趨向性，成果發表於 Cancer Research。
At the 2nd National Biotechnology Research Park Pitch Day (November 22, 2024), our team received the Outstanding New Drug Team Award — one of only three granted in the new drug category. Dr. Shih-Hsuan Chan accepted the award on behalf of the team led by Vice President Lu-Hai Wang, for HH0146, the first therapeutic humanized anti-CD24 antibody, which specifically activates macrophages and natural killer cells against metastatic triple-negative breast cancer.
於 2024 年 11 月 22 日舉行的第 2 屆「2024 NBRP Pitch Day 全國生醫轉譯選拔媒合會」中，本團隊榮獲新藥類傑出團隊獎（全國僅 3 隊獲獎），由詹世萱副教授代表王陸海副校長率領之團隊受獎。團隊自 2019 年率先提出抗 CD24 療法，開發首見治療性人源化 CD24 抗體 HH0146，可專一活化巨噬細胞增強吞噬能力，並活化自然殺手細胞毒殺腫瘤。
New study published in Journal of Biomedical Science reveals SCEL's role in regulating TNF-α/NF-κB axis to control lung colonization in triple-negative breast cancer.
發表於 Journal of Biomedical Science 的新研究揭示 SCEL 在調控 TNF-α/NF-κB 軸以控制三陰性乳癌肺部定植中的作用。